Thermo Fisher Scientific Stock: Analyst Estimates & Ratings
Thermo Fisher Scientific has trailed key benchmarks despite a Strong Buy consensus. Analysts forecast 9.8% diluted EPS growth to $25.12, while the mean price target of $635.08 implies 7.4% upside and the Street-high target suggests 26.8%.
Waltham, Massachusetts-based Thermo Fisher Scientific Inc. (TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, laboratory products and biopharma services internationally. The company has a market capitalization of $217.5 billion and operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Thermo Fisher shares gained 20.3% over the past year, slightly trailing the S&P 500 Index’s ($SPX) 20.4% advance. In 2026, TMO has risen nearly 1.5%, compared with a 13.7% gain for the SPX. The State Street Healthcare Select Sector SPDR ETF (XLV) outperformed Thermo Fisher in both periods, advancing 22.4% over the past year and 7.7% in 2026. The performance gap reflects concerns about the company’s fundamentals. Thermo Fisher has recorded no organic revenue growth over the past two years, while efficiency has declined over the last five years, as reflected in a falling operating margin. Diluted EPS decreased 1.4% annually over that period even as revenue grew, pointing to weaker profitability from sales. For the current year ending in December, analysts expect diluted EPS to rise 9.8% to $25.12. The company exceeded consensus estimates in each of the past four quarters, providing a potential earnings catalyst despite the broader profitability concerns. Among 26 analysts covering TMO, the consensus rating is “Strong Buy,” based on 20 “Strong Buy” ratings, one “Moderate Buy” and five “Hold” ratings. The configuration has remained unchanged in recent months. On July 29, J.P. Morgan analyst Casey Woodring maintained a “Buy” rating and raised his price target from $600 to $690. TMO’s mean target of $635.08 implies 7.4% upside from the current market price, while the Street-high target of $750 implies 26.8% upside. At publication, the related quotes were XLV at $174.62, $SPX at 7,674.37 and TMO at $629.27.